Irritable Bowel Syndrome (IBS) Treatment Market Research Report - Americas Forecast till 2027

Irritable Bowel Syndrome (IBS) Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Americas Forecast Till 2027

ID: MRFR/Pharma/4107-CR | February, 2018 | Region : Americas

Irritable Bowel Syndrome (IBS) Treatment Market Scenario


Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas Irritable bowel syndrome (IBS) treatment market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year. Additionally, According to a report of the National Institute of Mental Health, in 2015, approximately 16.1 adults over 18 years in the United States had at least one major depressive episode in the past one year, which is 6.7% of all the U.S. adults. These number generate the huge demand for better treatment in this region.


Hence, most of the companies are more into mergers, acquisitions, and collaboration activities in order to provide better treatment procedures. In this regard, Allergan Plc. in January 2017, entered into a licensing agreement with Assembly Biosciences, Inc. for worldwide rights to Assembly's microbiome GI development programs. Also, in October 2016, Allergan Plc. announced the formation of the IBS CounSEL, group of experts dedicated to improve diagnosis and management of irritable bowel syndrome (IBS) by providing support. These merger and acquisition help the companies to introduce quality treatment and expand the product line within the region. Companies are also focusing on research and development activities to get better approach to treat IBS. In this regard, in September 2017, Sucampo Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the application of supplemental new drug application (sNDA) for lubiprostone (AMITIZA) in children.


Furthermore, increasing consumer awareness about irritable bowel syndrome increase the footfall of patient in clinics and hospitals. Furthermore, increasing spending in the healthcare domain fuelling the growth of the IBS treatment market. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion. In 2016, healthcare spending in North America had increased to some extent.


However, strict FDA regulations and unsatisfactory effectiveness of the treatment may hinder the growth of America's Americas Irritable bowel syndrome (IBS) treatment market during the forecast period.


America's Irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023.


Research Methodology


 Americas IBS treatment


Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Irritable Bowel Syndrome (Ibs) Treatment Market Segmentation 


The Americas Irritable bowel syndrome (IBS) treatmen market is segmented on the basis of types, drugs type, and end user.


On the basis the types, irritable bowel syndrome (IBS) treatment market is segmented into IBS-D, IBS-C, IBS-M.


On the basis of the drugs type, irritable bowel syndrome (IBS) treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.


On the basis of the end users, irritable bowel syndrome (IBS) treatment market is segmented into hospitals, clinics, and research laboratories.


Figure: Americas Irritable bowel syndrome (IBS) treatment market, by type, 2016 (%)


 


Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


irritable bowel syndrome (IBS) treatment market Key Findings



  • The Americas Irritable bowel syndrome (IBS) treatmen market is estimated at USD 1,959.5 million in 2016.

  • IBS-C is the fastest growing segment, which is projected grow at a CAGR of 9.6% during the forecast period 2017-2023.

  • Linaclotide is the fastest growing drugs type segment, which is expected to USD 1,164.8 million by 2023.

  • The United States captured the largest market of Americas and is expected to USD 2,660.9 million by 2023.


Irritable Bowel Syndrome (Ibs) Treatment Market Regional Analysis


The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, the presence of strong economic conditions, and the focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of the market in this region. Also, the countries in this region have multiple companies that are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and a great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.


Irritable Bowel Syndrome (Ibs) Treatment Market Key Players


Some of the key players in this Americas Irritable bowel syndrome (IBS) treatment market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 

1 Report Prologue

2 Market Introduction

2.1 Scope of Study 11

2.2 Research Objective 11

2.3 Assumptions & Limitations 11

2.3.1 Assumptions 11

2.3.2 Limitations 11

2.4 Market Structure 12

3 Research Methodology

3.1.1 Primary Research Methodology 14

3.1.2 Data points received from the doctors/ gastrologist: 14

3.1.3 Data points received from the manufacturer/ pharmaceutical companies: 15

3.1.4 Data points received from Hospitals, Clinics: 15

3.1.5 Secondary Research Methodology 17

3.1.6 Market Share Analysis 19

3.1.7 Trade Analysis 19

3.1.8 Market Pricing Approach 19

4 Market Dynamics

4.1 Introduction 20

4.2 Drivers 21

4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%) 21

4.2.2 Strong clinical pipeline (Impact Weightage: 35%) 22

4.2.3 Increasing prevalence of depression (Impact Weightage: 28%) 23

4.3 Restraints 24

4.3.1 Strict FDA regulations (Impact Weightage: 60%) 24

4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%) 25

4.4 Opportunity 26

4.5 Mega Trends 27

4.6 Macroeconomic Indicators 28

5 Market Factor Analysis

5.1 Value Chain Analysis 29

5.1.1 Research and Development 29

5.1.2 Manufacturing 30

5.1.3 Distribution & Sales 30

5.1.4 Post-sales Monitoring 30

5.2 Porters Five Forces 31

5.2.1 Threat of New Entrants (Medium to High) 32

5.2.2 Bargaining power of suppliers (Medium) 32

5.2.3 Threat of Substitutes (Medium to High) 32

5.2.4 Bargaining Power of Buyers (Medium) 32

5.2.5 Intensity of Rivalry (Medium to High) 32

5.3 Demand & Supply: Gap Analysis 33

5.4 Pricing Analysis 33

5.5 Investment Opportunity Analysis 33

5.6 Merger and Acquisition Landscape 34

6 Americas IBS Treatment Market, By Type

6.1 Introduction 35

6.2 IBS-D 36

6.3 IBS-C 37

6.4 IBS-M 37

7 Americas IBS Treatment Market, By Drug Type

7.1 Introduction 38

7.2 Lubiprostone 39

7.3 Linaclotide 40

7.4 Eluxadoline 40

7.5 Rifaximin 40

7.6 Alosetron 41

8 Americas IBS Treatment Market, By End User

8.1 Introduction 42

8.2 Hospitals 43

8.3 Clinics 44

8.4 Research laboratories 44

9 Americas IBS treatment By Region

9.1 Introduction 45

9.1.1 North America 47

9.1.1.1 U.S. 48

9.1.1.2 Canada 50

9.1.2 South America 51

10 Company Landscape

11 Company Profiles

11.1 Allergan Plc 54

11.1.1 Company Overview 54

11.1.2 Financials 54

11.1.3 Products 54

11.1.4 Strategy 54

11.1.5 Key Developments 54

11.2 Sucampo Pharmaceuticals 55

11.2.1 Company Overview 55

11.2.2 Financials 55

11.2.3 Products 55

11.2.4 Strategy 55

11.2.5 Key Developments 55

11.3 Ironwood Pharmaceuticals, Inc. 56

11.3.1 Company Overview 56

11.3.2 Financials 56

11.3.3 Products 56

11.3.4 Strategy 56

11.3.5 Key Developments 56

11.4 Astellas Pharma Inc. 57

11.4.1 Company Overview 57

11.4.2 Financials 57

11.4.3 Products 57

11.4.4 Strategy 57

11.4.5 Key Developments 57

11.5 Valeant Pharmaceuticals 58

11.5.1 Company Overview 58

11.5.2 Financials 58

11.5.3 Products 58

11.5.4 Strategy 58

11.5.5 Key Developments 58

11.6 Abbott Laboratories 59

11.6.1 Company Overview 59

11.6.2 Financials 59

11.6.3 Products 59

11.6.4 Strategy 59

11.6.5 Key Developments 59

11.7 Synergy Pharmaceuticals, Inc. 60

11.7.1 Company Overview 60

11.7.2 Financials 60

11.7.3 Products 60

11.7.4 Strategy 60

11.7.5 Key Developments 60

11.8 Ardelyx, Inc. 61

11.8.1 Company Overview 61

11.8.2 Financials 61

11.8.3 Products 61

11.8.4 Strategy 61

11.8.5 Key Developments 61

11.9 Nestle 62

11.9.1 Company Overview 62

11.9.2 Financials 62

11.9.3 Products 62

11.9.4 Strategy 62

11.9.5 Key Developments 62

11.10 Sebela Pharmaceuticals 63

11.10.1 Company Overview 63

11.10.2 Financials 63

11.10.3 Products 63

11.10.4 Strategy 63

11.10.5 Key Developments 63

11.11 Probi 64

11.11.1 Company Overview 64

11.11.2 Financials 64

11.11.3 Products 64

11.11.4 Strategy 64

11.11.5 Key Developments 64

11.12 Alfasigma USA, Inc. 65

11.12.1 Company Overview 65

11.12.2 Financials 65

11.12.3 Products 65

11.12.4 Strategy 65

11.12.5 Key Developments 65

12 Conclusion

12.1 Key Findings 66

12.1.1 From CEO’s View Point 66

12.1.2 Unmet Needs 66

12.2 Key Companies to Watch 66

13 Appendix

13.1 Discussion Blue Print 67

14 List of tables

TABLE 1 PRIMARY INTERVIEWS 16

TABLE 2 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 35

TABLE 3 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36

TABLE 4 AMERICAS IBS TREATMENT MARKET FOR IBS-D SEGMENT, BY REGION, 2020-2027 (USD MILLION) 36

TABLE 5 AMERICAS IBS TREATMENT MARKET FOR IBS-C SEGMENT, BY REGION, 2020-2027 (USD MILLION) 37

TABLE 6 AMERICAS IBS TREATMENT MARKET FOR IBS-M SEGMENT, BY REGION, 2020-2027 (USD MILLION) 37

TABLE 7 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 38

TABLE 8 AMERICAS IBS TREATMENT MARKET FOR LUBIPROSTONE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 39

TABLE 9 AMERICAS IBS TREATMENT MARKET FOR LINACLOTIDE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 10 AMERICAS IBS TREATMENT MARKET FOR ELUXADOLINE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 11 AMERICAS IBS TREATMENT MARKET FOR RIFAXIMIN SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 12 AMERICAS IBS TREATMENT MARKET FOR ALOSETRON SEGMENT, BY REGION, 2020-2027 (USD MILLION) 41

TABLE 13 AMERICAS IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 42

TABLE 14 AMERICAS IBS TREATMENT MARKET FOR HOSPITALS SEGMENT, BY REGION, 2020-2027 (USD MILLION) 43

TABLE 15 AMERICAS IBS TREATMENT MARKET FOR CLINICS SEGMENT, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 16 AMERICAS IBS TREATMENT MARKET FOR RESEARCH LABORATORIES SEGMENT, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 17 AMERICAS IBS TREATMENT MARKET, BY REGION 2020-2027 (USD MILLION) 46

TABLE 18 NORTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 47

TABLE 19 NORTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 47

TABLE 20 NORTH AMERICA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 48

TABLE 21 U.S. IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 48

TABLE 22 U.S. IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 49

TABLE 23 U.S. IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 49

TABLE 24 CANADA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 50

TABLE 25 CANADA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 50

TABLE 26 CANADA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 51

TABLE 27 SOUTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 51

TABLE 28 SOUTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 52

TABLE 29 SOUTH AMERICA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 52

15 List of Figures

FIGURE 1 AMERICAS IBS TREATMENT MARKET SHARE, BY TYPE, 2020 (%) 10

FIGURE 2 AMERICAS IBS TREATMENT MARKET SHARE, BY DRUG TYPE, 2020 (%) 10

FIGURE 3 RESEARCH METHODOLOGY 13

FIGURE 4 DATA TRIANGULATION PRIMARY 16

FIGURE 5 DATA TRIANGULATION METHOD 18

FIGURE 6 VALUE CHAIN: IRRITABLE BOWEL SYNDROME 29

FIGURE 7 PORTERS FIVE FORCES MODEL 31

FIGURE 8 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2020 & 2027 (USD MILLION) 39

FIGURE 9 AMERICAS IBS TREATMENT MARKET, BY END USER, 2020 & 2027 (USD MILLION) 43

FIGURE 10 AMERICAS IBS TREATMENT MARKET, BY REGION MARKET SHARE, 2020 (%) 46

FIGURE 11 AMERICAS IBS TREATMENT COMPANY MARKET SHARE, 2020 (%) 53

IBS Treatment Market